Doseology Announces Management Cease Trade Order for Late Filing of Annual Audited Financial Statements
The order permits continued share trading by persons other than company insiders and employees while annual filings remain overdue.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Doseology Sciences (DOSEF) received a management cease trade order after missing the October 28, 2026 deadline for its annual filings.
The overdue documents cover the year ended June 30, 2026 and include audited financial statements, management's discussion and analysis, and related certifications. Trading in common shares may continue for persons other than insiders and employees. The company expects its auditor to need approximately two additional weeks and anticipates filing on or before November 15, 2026. Doseology will issue bi-weekly default status reports while the filing default continues.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Hollow bars mark forward-looking points. How the balance works
Positive
- Minor pointCommon-share trading may continue for persons other than insiders and employees under the management cease trade order.
Negative
- Major pointAnnual filings for the year ended June 30, 2026 missed the October 28, 2026 deadline.
- Minor pointManagement cease trade order restricts trading by company insiders and employees.
- Minor point. Forward-looking: it has not happened yet and may not happen.Audit completion requires approximately two additional weeks, the company anticipates; filing is expected by November 15, 2026.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Kelowna, British Columbia--(Newsfile Corp. - October 29, 2026) - Doseology Sciences Inc. (CSE: MOOD) (OTCQB: DOSEF) (FSE: VU70) ("Doseology" or the "Company"), a consumer product innovation company focused on oral pouch and functional stimulant product technologies, announces that it was unable to file its annual audited financial statements, management's discussion and analysis and related certifications for the year ended June 30, 2026 (the "Annual Filings") on or before the prescribed filing deadline of October 28, 2026, as required by National Instrument 51-102 Continuous Disclosure Obligations, and National Instrument 52-109 Certification of Disclosure in Issuers' Annual and Interim Filings, respectively.
The Company advises that the delay in filing its audited financial statements for the year ended June 30, 2026, together with the related management's discussion and analysis and CEO/CFO certifications (collectively, the "Annual Filings"), is not the result of any unresolved accounting matters, outstanding information requests, or delays by management.
The Company anticipates that its auditor will need approximately two additional weeks to complete the audit of the Company's annual financial statements.
Accordingly, the Company applied for and received a management cease trade order under the provisions of National Policy 12-203 Management Cease Trade Orders ("NP 12-203") so as to permit the continued trading in the Company's common shares by persons other than insiders and employees of the Company.
The Company's staff is working diligently with its auditors and anticipates that it will file its Annual Filings on or before November 15, 2026. The Company confirms that it will comply with the alternative information guidelines included in NP 12-203 and will issue bi-weekly default status reports for so long as the Company remains in default of the financial statement filing requirement, containing any material changes to the information in this release, all actions taken by the Company to remedy the default; particulars of any failure by the Company to fulfill these provisions, any subsequent defaults of the Company requiring a default announcement and any other material information concerning the affairs of the Company not previously disclosed. The Company is not subject to any insolvency proceedings nor is there in other material information concerning the affairs of the Company that has not been generally disclosed.
About Doseology Sciences Inc. (CSE: MOOD) (OTCQB: DOSEF) (FSE: VU70)
Doseology Sciences Inc. specializes in pouch-based oral stimulant and cognitive support products. The rapidly expanding oral stimulant pouch sector is gaining momentum as consumers seek modern, discreet alternatives to traditional delivery formats. Unlike combustible tobacco or vape products, oral stimulant pouches are smokeless and vapor-free, providing an alternative delivery method without inhalation.
From a market perspective, the oral pouch category is experiencing strong global growth as consumers increasingly prioritize convenience, portability, and format innovation. The pouch sector represents one of the most dynamic and high-growth areas in modern functional consumer products.
For more information, visit:
Corporate: www.doseology.com
On behalf of the Board of Directors,
Kareem Baalbaki
Interim CEO
Doseology Sciences Inc.
Investor & Media Contact:
Email: hello@doseology.com
Phone: 825.800.0115
No securities regulatory authority has either approved or disapproved of the contents of this press release.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/321705
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
When does Doseology expect to file its overdue annual financial statements?
Doseology anticipates filing its annual documents on or before November 15, 2026. These cover the year ended June 30, 2026 and include audited financial statements, management's discussion and analysis, and CEO/CFO certifications.